These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9643490)

  • 21. Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus.
    Giménez A; Minguela A; Parrilla P; Bermejo J; Pérez D; Molina J; García AM; Ortiz MA; Alvarez R; de Haro LM
    Cancer; 1998 Aug; 83(4):641-51. PubMed ID: 9708926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
    Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG
    Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
    Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
    Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study.
    Canto MI; Setrakian S; Willis JE; Chak A; Petras RE; Sivak MV
    Endoscopy; 2001 May; 33(5):391-400. PubMed ID: 11396755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accuracy of endoscopic optical coherence tomography in the detection of dysplasia in Barrett's esophagus: a prospective, double-blinded study.
    Isenberg G; Sivak MV; Chak A; Wong RC; Willis JE; Wolf B; Rowland DY; Das A; Rollins A
    Gastrointest Endosc; 2005 Dec; 62(6):825-31. PubMed ID: 16301020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression.
    Weston AP; Banerjee SK; Sharma P; Tran TM; Richards R; Cherian R
    Am J Gastroenterol; 2001 May; 96(5):1355-62. PubMed ID: 11374668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett's Esophagus.
    Vennalaganti P; Kanakadandi V; Goldblum JR; Mathur SC; Patil DT; Offerhaus GJ; Meijer SL; Vieth M; Odze RD; Shreyas S; Parasa S; Gupta N; Repici A; Bansal A; Mohammad T; Sharma P
    Gastroenterology; 2017 Feb; 152(3):564-570.e4. PubMed ID: 27818167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
    Wani S; Rubenstein JH; Vieth M; Bergman J
    Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
    Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH
    J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Dysplasia in Barrett's esophagus--intra- and interobserver variability in histopathological diagnosis].
    Lopes CV; Pereira-Lima JC; Hartmann AA; Tonelotto E; Salgado K
    Arq Gastroenterol; 2004; 41(2):79-83. PubMed ID: 15543378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substantial Interobserver Agreement in the Diagnosis of Dysplasia in Barrett Esophagus Upon Review of a Patient's Entire Set of Biopsies.
    Salomao MA; Lam-Himlin D; Pai RK
    Am J Surg Pathol; 2018 Mar; 42(3):376-381. PubMed ID: 29135518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma.
    Kim R; Clarke MR; Melhem MF; Young MA; Vanbibber MM; Safatle-Ribeiro AV; Ribeiro U; Reynolds JC
    Dig Dis Sci; 1997 Dec; 42(12):2453-62. PubMed ID: 9440619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time gated fluorescence spectroscopy in Barrett's oesophagus.
    Ortner MA; Ebert B; Hein E; Zumbusch K; Nolte D; Sukowski U; Weber-Eibel J; Fleige B; Dietel M; Stolte M; Oberhuber G; Porschen R; Klump B; Hörtnagl H; Lochs H; Rinneberg H
    Gut; 2003 Jan; 52(1):28-33. PubMed ID: 12477755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to pre-set benchmark quality criteria to qualify as expert assessor of dysplasia in Barrett's esophagus biopsies - towards digital review of Barrett's esophagus.
    van der Wel MJ; Klaver E; Duits LC; Pouw RE; Seldenrijk CA; Offerhaus G; Visser M; Ten Kate F; Biermann K; Brosens L; Doukas M; Huysentruyt C; Karrenbeld A; Kats-Ugurlu G; van der Laan JS; van Lijnschoten G; Moll F; Ooms A; Tijssen JG; Bergman J; Meijer SL
    United European Gastroenterol J; 2019 Aug; 7(7):889-896. PubMed ID: 31428413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus.
    Hamelin R; Fléjou JF; Muzeau F; Potet F; Laurent-Puig P; Fékété F; Thomas G
    Gastroenterology; 1994 Oct; 107(4):1012-8. PubMed ID: 7523212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular evaluation of ablative therapy of Barrett's oesophagus.
    Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
    J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The utility of P53 immunohistochemistry in the diagnosis of Barrett's oesophagus with indefinite for dysplasia.
    Januszewicz W; Pilonis ND; Sawas T; Phillips R; O'Donovan M; Miremadi A; Malhotra S; Tripathi M; Blasko A; Katzka DA; Fitzgerald RC; di Pietro M
    Histopathology; 2022 Jun; 80(7):1081-1090. PubMed ID: 35274753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett's dysplasia.
    Wani S; Mathur SC; Curvers WL; Singh V; Alvarez Herrero L; Hall SB; Ulusarac O; Cherian R; McGregor DH; Bansal A; Rastogi A; Ahmed B; Singh M; Gaddam S; Ten Kate FJ; Bergman J; Sharma P
    Clin Gastroenterol Hepatol; 2010 Sep; 8(9):783-8. PubMed ID: 20472096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Observer variation in the diagnosis of dysplasia in Barrett's esophagus.
    Reid BJ; Haggitt RC; Rubin CE; Roth G; Surawicz CM; Van Belle G; Lewin K; Weinstein WM; Antonioli DA; Goldman H
    Hum Pathol; 1988 Feb; 19(2):166-78. PubMed ID: 3343032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Reproducibility of histological criteria of dysplasia in Barrett mucosa].
    Sagan C; Fléjou JF; Diebold MD; Potet F; Le Bodic MF
    Gastroenterol Clin Biol; 1994; 18(1 Pt 2):D31-4. PubMed ID: 8013780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.